Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
about
HER2-positive gastric cancer identified by serum HER2: A case report.Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
P2860
Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Serum HER2 as an adjunct to as ...... multicenter trial (SHERLOCK).
@en
Serum HER2 as an adjunct to as ...... prospective multicenter trial
@nl
type
label
Serum HER2 as an adjunct to as ...... multicenter trial (SHERLOCK).
@en
Serum HER2 as an adjunct to as ...... prospective multicenter trial
@nl
prefLabel
Serum HER2 as an adjunct to as ...... multicenter trial (SHERLOCK).
@en
Serum HER2 as an adjunct to as ...... prospective multicenter trial
@nl
P2093
P2860
P1433
P1476
Serum HER2 as an adjunct to as ...... multicenter trial (SHERLOCK).
@en
P2093
Akira Goto
Atsushi Yawata
Hiroyuki Kaneto
Hiroyuki Okuda
Kazuya Suzuki
Kentaro Yamashita
Kohei Nakachi
Mariko Kawayama
Mayuko Saito
Mitsuru Yoshimoto
P2860
P304
P356
10.3109/0284186X.2015.1107189
P577
2016-01-12T00:00:00Z